Stage III Breast Cancer Recruiting Phase 2 Trials for Alisertib (DB05220)

IndicationStatusPhase
DBCOND0031775 (Stage III Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02860000Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerTreatment